Gan & Lee Pharmaceuticals Inc. (603087)
Market Open
10 Aug, 06:57
SSE SSE Primary ¥
67. 70
-1.99
-2.8555%
¥
27.4B Market Cap
- P/E Ratio
0.8% Div Yield
12.67M Volume
- Eps
¥ 69.69
Previous Close Want to track 603087 and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
603087 trading today lower at ¥67.7, a decrease of -2.8555% from yesterday's close, completing a monthly increase of 19.4214% or ¥11.01. Over the past 12 months, 603087 stock lost -0.3386%.
603087 pays dividends to its shareholders, with the most recent payment made on May 29, 2026. The next estimated payment will be in In 9 months on May 29, 2027 for a total of ¥1.
The last earnings report, released on Apr 23, 2026, missed the consensus estimates by -0.45%. On average, the company has fell short of earnings expectations by -0.21%, based on the last three reports.
Gan & Lee Pharmaceuticals Inc. has completed 1 stock splits, with the recent split occurring on Aug 20, 2020.
The company's stock is traded on one exchange.
603087 Chart
People also search for
Gan & Lee Pharmaceuticals Inc. (603087) FAQ
What is the stock price today?
The current price is ¥67.70.
On which exchange is it traded?
Gan & Lee Pharmaceuticals Inc. is listed on SSE.
What is its stock symbol?
The ticker symbol is 603087.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 0.8%.
What is its market cap?
As of today, the market cap is 27.4B.
Has Gan & Lee Pharmaceuticals Inc. ever had a stock split?
Gan & Lee Pharmaceuticals Inc. had 1 splits and the recent split was on Aug 20, 2020.
Gan & Lee Pharmaceuticals Inc. Profile
| Electronic Equipment, Instruments & Components Industry | Information Technology Sector | Mr. Gan Zhongru Ph.D. CEO | SSE Exchange | CNE100003ZH1 ISIN |
| CN Country | 4,482 Employees | 29 May 2026 Last Dividend | 20 Aug 2020 Last Split | - IPO Date |
Overview
Gan & Lee Pharmaceuticals is a prominent biopharmaceutical company that operates out of Beijing, China, focusing extensively on the research, development, production, and marketing of insulin analog active pharmaceutical ingredients (APIs) and injections. Since its establishment in 1998, originally as Beijing Gan & Lee Biotechnology Co., Ltd., the company has been at the forefront of diabetes management solutions. In April 2005, a strategic decision was made to change the company name to Gan & Lee Pharmaceuticals, marking a significant milestone in its journey towards becoming a key player in the pharmaceutical industry within the People's Republic of China and beyond.
Products and Services
- Basalin - This product is an insulin glargine injection designed for the long-lasting regulation of blood sugar levels in individuals with diabetes.
- Prandilin - Prandilin is an insulin lispro and lispro mix 75/25 injection. It caters to the need for a fast-acting insulin option, suitable for managing blood sugar levels around meal times.
- Prandilin 25 - As a variation of Prandilin, Prandilin 25 is specifically an insulin lispro injection, tailored for rapid action to control blood sugar spikes after meals.
- Rapilin - Rapilin, an insulin aspart injection, offers another swift-acting insulin alternative, facilitating close blood sugar level management for diabetics.
- Rapilin 30 - Similar to Rapilin, Rapilin 30 is an insulin aspart 30 injection that provides all the benefits of insulin aspart with a specific mixture proportion for optimized diabetes control.
- Similin 30 - This insulin injection is designed for people who require a stable insulin intake regimen, providing a well-rounded solution for diabetes management.
- GanleePen - GanleePen is an innovative insulin injection device that emphasizes ease of use, accuracy, and convenience for users who require regular insulin administration.
- GanleeFine - Complementing the GanleePen, GanleeFine consists of insulin pen needles crafted for a comfortable and precise insulin delivery experience.
- Medical Devices - In addition to insulin and related products, Gan & Lee Pharmaceuticals extends its portfolio to include various medical devices, further supporting diabetes management and patient care.
Contact Information
Address: No. 8, Nanfeng West 1st Street, Beijing, China, 101109
Phone: 86 10 8059 3699
Website: https://www.ganlee.com
